{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:04:14Z","timestamp":1756425854463,"version":"3.44.0"},"reference-count":11,"publisher":"BMJ","issue":"7","funder":[{"name":"Ministry of Health, Labor, and Welfare, Japan","award":["210901-02"],"award-info":[{"award-number":["210901-02"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,6,17]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>A man in his 70s was detected an infiltrative shadow on the right lung. A bronchoscopy confirmed the diagnosis of adenocarcinoma of the lung, classified as cT2bN2M0 stage IIIA, with a deletion mutation in <jats:italic>EGFR<\/jats:italic> exon 19. Weekly carboplatin plus paclitaxel was administered in combination with thoracic radiotherapy, followed by maintenance therapy with durvalumab for 1\u2009year. Four months later, he was diagnosed with a recurrence of adenocarcinoma in the lung. He started treatment with osimertinib. Six months after initiating osimertinib, a chest CT revealed bilateral pleural effusion and expansion of the inferior vena cava. Eleven months later, he entered our emergency department with progressive dyspnoea. A chest CT showed bilateral massive pleural effusion and cardiac enlargement. He was diagnosed with osimertinib-induced cardiac failure. Osimertinib was discontinued, and echocardiology demonstrated a gradual improvement in cardiac function. It is necessary to take care of osimertinib-related cardiotoxicity.<\/jats:p>","DOI":"10.1136\/bcr-2023-255245","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:25:36Z","timestamp":1689945936000},"page":"e255245","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung"],"prefix":"10.1136","volume":"16","author":[{"given":"Takaaki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Medical Oncology, Okayama Rosai Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soma","family":"Nii","sequence":"additional","affiliation":[{"name":"Internal Medicine, Okayama Rosai Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenaru","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Okayama Rosai Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-0433","authenticated-orcid":false,"given":"Nobukazu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Medical Oncology, Okayama Rosai Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2025082804073208000_16.7.e255245.1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2025082804073208000_16.7.e255245.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"2025082804073208000_16.7.e255245.3","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8344-16"},{"key":"2025082804073208000_16.7.e255245.4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms131012268"},{"key":"2025082804073208000_16.7.e255245.5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025082804073208000_16.7.e255245.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025082804073208000_16.7.e255245.7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.7644-21","article-title":"Durvalumab-associated late-onset myocarditis successfully treated with corticosteroid therapy","volume":"61","author":"Maetani","year":"2022","journal-title":"Intern Med"},{"key":"2025082804073208000_16.7.e255245.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz077"},{"key":"2025082804073208000_16.7.e255245.9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2020.10.021","article-title":"Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction","volume":"153","author":"Kunimasa","year":"2021","journal-title":"Lung Cancer"},{"key":"2025082804073208000_16.7.e255245.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000745"},{"key":"2025082804073208000_16.7.e255245.11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-255245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:07:38Z","timestamp":1756379258000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-255245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,21]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bcr-2023-255245"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-255245","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}